Juka Soohyang Kim

Dr. Juka Soohyang Kim

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in Clinical Transplantation
Verified
Journal Article
Closed access
YXYu Xia
Yu Xia
JKJuka Soohyang Kim
Juka Soohyang Kim
IEIsabel K. Eng
Isabel K. Eng
ANAli Nsair
Ali Nsair
AAAbbas Ardehali
Abbas Ardehali
MKMurray H. Kwon
Murray H. Kwon

26 December 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
JKJuka Soohyang Kim
Juka Soohyang Kim
TBTaylor K. Brashear
Taylor K. Brashear
BCBriana Collins
Briana Collins
HVHannah Valantine
Hannah Valantine
KKKiran K. Khush
Kiran K. Khush
JNJoyce N. Njoroge
Joyce N. Njoroge
Cardiac allograft vasculopathy (CAV) remains a leading cause of mortality among heart transplant recipients with morbid complications, including graft dysfunction, arrhythmias, and sudden cardiac death. While few medications may reduce the incidence of CAV, the only true treatment for prevalent severe CAV is retransplantation. Current practice is limited, with few validated tools for predicting these complications or informing appropriate timing for retransplantation. In this review, we highlight novel molecular and imaging markers of CAV incidence and prognosis and propose future applications to improve precise risk stratification and management of CAV.

16 February 2024 in Medical Education
Verified
Journal Article
Open access
JKJuka Soohyang Kim
Juka Soohyang Kim
KLKaren L. Leung
Karen L. Leung
IEIsabel K. Eng
Isabel K. Eng
ASAparna Sridhar
Aparna Sridhar

1 March 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
PKPreetham Kumar
Preetham Kumar
JKJuka Soohyang Kim
Juka Soohyang Kim
JGJonathan Gordin
Jonathan Gordin
HHHenry M. Honda
Henry M. Honda
WSWilliam Suh
William Suh
RPRushi V. Parikh
Rushi V. Parikh

28 May 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
PDF file
DBDavid J. Bae
David J. Bae
SWSubeer K. Wadia
Subeer K. Wadia
JKJuka Soohyang Kim
Juka Soohyang Kim
EMElan Moreno
Elan Moreno
Reza ArdehaliReza Ardehali
Reza Ardehali
MKMurray H. Kwon
Murray H. Kwon
Objective Unrecognized left ventricular thrombi (LVT) can have devastating clinical implications and precludes patients with end-stage heart failure from undergoing left ventricular assist device (LVAD) implantation without cardiopulmonary bypass assistance. We assessed the reliability of an echocardiogram to diagnose LVT in patients with end-stage heart disease who underwent LVAD implantation. Methods A single-center retrospective study evaluated 232 consecutive adult patients requiring implantation of durable LVADs between 2005 and 2019. The validity of preoperative transthoracic echocardiogram (TTE) and intraoperative transesophageal echocardiogram (TEE) for diagnosing LVT was compared to direct inspection at the time of LVAD implantation. Results There were 232 patients that underwent LVAD implantation, with 226 patients (97%) receiving a preoperative TTE. Of those 226 patients, 32 patients (14%) received ultrasound enhancing agents (UEA). Intraoperative TEE images were available in 195 patients (84%). The sensitivity of TTE without UEA was 22% and specificity was 90% for detecting LVT, compared to 50% and 86%, respectively, for TTE with UEA. For intraoperative TEE, the sensitivity and specificity were 46% and 96%, respectively. The false omission rate ranged from 4% to 8% for all modalities of echocardiography. Conclusion Among patients undergoing LVAD implantation, preoperative TTE and intraoperative TEE had poor sensitivity for LVT detection. Up to 8% of echocardiograms were incorrectly concluded to be negative for LVT on surgical validation. The low sensitivity and positive predictive value for diagnosing LVT suggest that echocardiography has limited reliability in this cohort of patients who are at high risk of LVT formation and its subsequent complications.

20 May 2026 in JACC: Heart Failure
Verified
Journal Article
Open access
COChristian O’DOnnell
Christian O’DOnnell
JKJuka Soohyang Kim
Juka Soohyang Kim
ATAkansha Tarun
Akansha Tarun
BCBettia E. Celestin
Bettia E. Celestin
AKAlexander K. Karius
Alexander K. Karius
KKKiran K. Khush
Kiran K. Khush
Current guidelines recommend screening donor hearts for hypertrophy using solely left ventricular (LV) wall thickness measurements, but this does not capture the type of LV geometric remodeling. Remodeling patterns have been shown to be predictive of clinical outcomes in many cardiovascular diseases but have not been evaluated in donor heart assessment. The purpose of this study was to describe the prevalence and clinical impact of geometric remodeling patterns in brain-dead donor heart acceptance and recipient survival. The DHS (Donor Heart Study) collected echocardiograms from brain-dead donors across the United States from February 2015 to May 2020. Donor hearts were classified by LV geometric remodeling patterns using ASE (American Society of Echocardiography) guidelines and were compared with LV wall thickness measurements of >1.3 cm for the association with transplant acceptance and 3-year recipient mortality, using multivariable modeling. Concentric remodeling (58.5%) was the most common geometric remodeling pattern in 3,647 brain dead donors. Donor hearts with increased LV wall thickness (>1.3 cm) were more likely reclassified as concentric remodeling (52.1%) than concentric hypertrophy (43.8%). Donors with nonacceptance surveys (n = 1,874) commonly (20.3%) had LV hypertrophy listed as a reason for rejection, but most of those hearts had normal geometry (10.8%) or concentric remodeling (60.0%). Neither increased LV wall thickness (adjusted HR [aHR]: 0.94; 95% CI: 0.73-1.21), concentric remodeling (aHR: 1.13; 95% CI: 0.86-1.47), nor concentric hypertrophy (aHR: 0.64; 95% CI: 0.35-1.15) correlated with 3-year recipient survival. Classifying donor hearts using LV geometric remodeling patterns may reduce the number turned down for "hypertrophy" without compromising recipient survival.